TY - JOUR
T1 - Treatment results and prognostic factors in primary thyroid lymphoma patients
T2 - A Rare Cancer Network study
AU - Onal, C.
AU - Li, Y. X.
AU - Miller, R. C.
AU - Poortmans, P.
AU - Constantinou, N.
AU - Weber, D. C.
AU - Atasoy, B. M.
AU - Igdem, S.
AU - Ozsahin, M.
AU - Ozyar, E.
PY - 2011/1
Y1 - 2011/1
N2 - Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5-and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.
AB - Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5-and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.
KW - Chemotherapy
KW - Combined modality treatment
KW - Non-Hodgkin's lymphoma
KW - Prognostic factors
KW - Radiotherapy
KW - Thyroid lymphoma
UR - http://www.scopus.com/inward/record.url?scp=78650394510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650394510&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdq310
DO - 10.1093/annonc/mdq310
M3 - Article
C2 - 20587509
AN - SCOPUS:78650394510
SN - 0923-7534
VL - 22
SP - 156
EP - 164
JO - Annals of Oncology
JF - Annals of Oncology
IS - 1
ER -